#mrnavaccines

[lasseling]

Investigation Reveals Presence of HIV-Infected Green Monkey DNA in COVID-19 Vaccines (VIDEO)

HIV-infected green monkey DNA has been discovered in both Pfizer and Moderna's mRNA COVID-19 vaccines, according to a recent study.

[manoasha]

Biotechnology Innovations in Medicine: A Comprehensive Exploration

Biotechnology has emerged as a transformative force in the field of medicine, bringing forth a wave of innovations that have significantly impacted healthcare. This article delves into the evolution of biotechnology in medicine, highlighting its benefits, examining the historical context, evaluating the current landscape, and envisioning the future prospects. **1. Benefits of Biotechnology in…

[enterprisewired]

Novel mRNA Vaccine Shows Promise in Combating High-Risk Melanoma: Trial Results

An experimental mRNA vaccine, in combination with immunotherapy, exhibits significant promise in addressing high-risk forms of melanoma, according to recent reports from the drugmakers involved in the trial.

Trial Results: Promising Outcomes in High-Risk Melanoma

In a three-year follow-up of participants who had undergone complete removal of stage III or IV melanoma but remained at a high risk of cancer recurrence, those who received the mRNA vaccine from Moderna in conjunction with Merck’s Keytruda immunotherapy demonstrated notable advantages. The joint treatment showcased a 49% reduction in the risk of cancer recurrence or death. Additionally, there was a 62% lower risk of distant tumor cell spread or death compared to those who solely received Keytruda, the companies highlighted in a recent press release.

Progressive Benefits Over Time

The findings built upon the earlier two-year follow-up, which reported a 44% lower risk of recurrence or death and a 65% lower risk of distant metastasis or death among individuals who received both Keytruda and the mRNA vaccine, known as mRNA-4157/V940, compared to those treated solely with Keytruda.

Safety Profile and Adverse Events

However, around a quarter of the trial participants receiving Keytruda alongside the vaccine reported experiencing serious adverse events attributed to the treatment. This figure stood at about 20% for those treated solely with Keytruda. Common side effects associated with the vaccine included fatigue, pain at the injection site, and chills.

Regulatory Status and Future Prospects

The US Food and Drug Administration (FDA) granted a breakthrough therapy designation to mRNA-4157/V940 in combination with Keytruda, acknowledging its potential as a significant advancement over existing therapies. This status expedites the development and review process of drugs aimed at treating severe conditions.

While the data from the Phase 2b trial has not undergone peer review or publication in a professional journal, Moderna and Merck have initiated Phase 3 trials focusing on stage IIB-IV melanoma and non-small-cell lung cancer. Their future plans involve expanding research to encompass a wider spectrum of tumor types.

Melanoma Statistics and Impact

Melanoma, accounting for just 1% of all skin cancers, contributes to a majority of skin cancer-related fatalities, as highlighted by the American Cancer Society. In 2023, it was estimated that nearly 100,000 new melanoma cases would be diagnosed in the US, leading to nearly 8,000 fatalities attributed to the disease.

As research and trials progress, the collaborative efforts between Moderna and Merck offer promising prospects in addressing the challenges posed by high-risk melanoma, potentially reshaping treatment protocols and outcomes for affected individuals.

Curious to learn more? Explore our articles on Enterprise Wired

[mikyit]

--- Merck, Moderna unveil phase 3 trial 🧪⚗️ details for closely watched #mRNA 🧬 #cancer#vaccine 💉 ---

The two #pharmaceutical firms revealed an update on results demonstrating an improved distant metastasis-free survival (DMFS) when their #mRNA#vaccine was used in combination with #Keytruda (pembrolizumab), at the 2023 American Society of Clinical Oncology (#ASCO) Annual Meeting.

[lovelypol]

"Strategic Forecast of the Influenza Vaccine Market 2024-2033"

From 2024 to 2033, the landscape of influenza vaccines is undergoing a transformative evolution, driven by advanced biotechnology and a focus on personalized medicine. The development of mRNA-based vaccines is accelerating, offering higher efficacy and faster production times. Universal flu vaccines targeting multiple strains are becoming a reality, reducing the need for annual updates. AI and big data analytics are enhancing predictive models for flu outbreaks, enabling more precise vaccine formulations. Additionally, needle-free delivery systems and improved cold chain logistics are making vaccines more accessible globally.

#FluVaccine2024 #mRNAVaccine #BiotechInnovation #PersonalizedMedicine #UniversalFluVaccine #AIInHealthcare #PredictiveAnalytics #VaccineEfficacy #ColdChainLogistics #NeedleFreeVaccines #GlobalHealth #VaccineAccess #FutureOfVaccines #HealthTech #MedicalInnovation #PublicHealth #VaccineResearch #FluPrevention #NextGenVaccines #DigitalHealth

[lasseling]

UK To Install Defibrillators in EVERY School Due to Sudden Rise in Heart Problems

The British government is set to pass a new law that would require all schools to install defibrillators due to the sudden rise in heart problems among fully jabbed children.

[wissenresearchllc]

𝐦𝐑𝐍𝐀 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬

"Vaccines prevent diseases and save lives."

Traditional vaccines contain an attenuated or dead form of the pathogen to stimulate the immune response, but mRNA vaccines use nucleic acid RNA. François Jacob and Jacques Monod discovered mRNA in the 1960s, and scientists have since been studying its potential for treating various diseases. mRNA instructs cells to make proteins, allowing the immune system to recognize and fight against invading antigens. mRNA vaccines are composed of artificial mRNA molecules that instruct the production of antibodies and generate an immune response, which distinguishes them from traditional vaccines. Key players in the mRNA vaccine field include Moderna, BioNTech, Pfizer, and more. The future of mRNA vaccines is promising and holds great potential to protect against various diseases.

Want to know more about mRNA Vaccines? Visit the link:

https://bit.ly/3kzg7I7

#mrnavaccines#COVID19Vaccines#science#healthcare#publichealth#vaccinesaveslives#medicalresearch#innovation#coronavirusvaccine#immunization#globalhealth#pharmaceuticals#biotechnology#researchanddevelopment#wissenresearch

[elainaledoyen]

BioNTech in Germany is one of two companies (the other being Moderna in the US) that have successfully developed mRNA vaccines against SARS-CoV-2, the virus responsible for COVID-19. BioNTech has now published research1 done in collaboration with researchers from Johannes Gutenberg University (Mainz, Germany) demonstrating in mice that another mRNA vaccine it has developed may eventually become a successful treatment for multiple sclerosis (MS) in humans.

[lasseling]

Every Person Who Received mRNA Vaccines Will Develop Cancer, Top Study Confirms

[ijtsrd]

Confirmation of Safety of COVID 19 mRNA Vaccination for Cancer Patients

by Takuma Hayashi | Nobuo Yaegashi | Ikuo Konishi "Confirmation of Safety of COVID-19 mRNA Vaccination for Cancer Patients"

Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021,

URL: https://www.ijtsrd.compapers/ijtsrd42563.pdf

Paper URL: https://www.ijtsrd.commedicine/other/42563/confirmation-of-safety-of-covid19-mrna-vaccination-for-cancer-patients/takuma-hayashi

internationaljournalsofcomputerscience, callforpapercomputerscience, ugcapprovedjournalsforcomputerscience

Patients in the active phase of treatment for cancer are a population at risk of coronavirus disease 19 COVID 19 with poor prognosis. While a majority of patients treated for cancer expressed their will to be vaccinated as early as December 2020 in a French survey, no data were available in terms of vaccine efficacy and tolerance, because they were excluded from initial registration trials. Several clinical facilities aimed to assess the safety and immunogenicity of the BNT162b2 Pfizer–BioNTech vaccine in patients with cancer. In patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. However, the anti SARS CoV 2 immune response was lower in patients with solid tumors who were vaccinated a second dose of BNT162b2 vaccine than in healthy individuals. These data support prioritization of patients with cancer for an early day 21 second dose of the BNT162b2 vaccine. 

[elainaledoyen]

Detection of mutations arising in the genome of the SARS-CoV-2 virus responsible for COVID-19 have led to concerns that new forms of the virus might enable it to evade the protection conferred by recently approved mRNA vaccines. Two strains in particular, B.1.1.7 from England and B.1.351 from South Africa, are driving the unease. B.1.1.7, first reported in September 2020, has been shown to be more transmissible than the previous strain and is spreading globally. The South African mutant was reported in mid-December 2020 by health authorities there as becoming the chief variant, an indication of heightened transmissibility. This strain garnered additional attention because the portion of Novavax’s Phase 3 vaccine trial conducted in South Africa showed noticeably lower efficacy there than in the UK portion.